Q4 2025 Adaptive Biotechnologies Corp Earnings Call Transcript
Key Points
- Adaptive Biotechnologies Corp (ADPT) achieved a 46% year-over-year revenue growth in their MRD business, surpassing profitability expectations.
- The company successfully integrated ClonoSeek into Flatiron's Onco EMR, expanding access across community settings.
- Adaptive Biotechnologies Corp (ADPT) launched NovaSeek X Plus, which is expected to scale operations and improve margins.
- The company secured its first Medicare coverage for recurrence monitoring in MCL, enhancing the lifetime value of each MCL Medicare patient.
- Adaptive Biotechnologies Corp (ADPT) reported a 68% reduction in cash burn, ending the year with a strong cash balance of $227 million.
- The company faces potential execution risks related to renegotiating two large payer contracts, which could impact ASP growth.
- There are concerns about incoming competition in the DLBCL space, which may affect market penetration.
- Weather-related issues in Q1 could impact sample arrival timing and volume, potentially affecting sequential growth.
- The company decided to stop further investment in its lead antibody program in ankylosing spondylitis, prioritizing capital toward data generation and AI modeling.
- Adaptive Biotechnologies Corp (ADPT) anticipates a high cash utilization in Q1 due to annual corporate bonus payments, which may affect cash flow.
Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies 4th quarter and full year earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.
To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised.
To withdraw your question, please press star 11 again.
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Karina Calzadilla, Vice President of Investor Relations. Please go ahead.
Thank you, Danielle, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies fourth quarter and full year 2025 earnings conference call. Earlier today, we issued a press release reporting adaptive financial results for the fourth quarter and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
